KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBIT Margin (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed EBIT Margin for 16 consecutive years, with 109.95% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin rose 9736.0% year-over-year to 109.95%, compared with a TTM value of 75.93% through Sep 2025, up 34237.0%, and an annual FY2024 reading of 270.3%, up 38431.0% over the prior year.
  • EBIT Margin was 109.95% for Q3 2025 at TherapeuticsMD, down from 73.0% in the prior quarter.
  • Across five years, EBIT Margin topped out at 70.65% in Q4 2022 and bottomed at 4269.25% in Q2 2022.
  • Average EBIT Margin over 5 years is 966.48%, with a median of 221.63% recorded in 2025.
  • The sharpest move saw EBIT Margin crashed -411631bps in 2022, then soared 370358bps in 2023.
  • Year by year, EBIT Margin stood at 37.75% in 2021, then surged by 287bps to 70.65% in 2022, then plummeted by -554bps to 320.92% in 2023, then surged by 114bps to 45.73% in 2024, then tumbled by -340bps to 109.95% in 2025.
  • Business Quant data shows EBIT Margin for TXMD at 109.95% in Q3 2025, 73.0% in Q2 2025, and 221.63% in Q1 2025.